Otsuka Holdings
在场
是其中之一......
Otsuka Holdings 是一家在股票代码 4578 (JP) 下上市的公司。
Otsuka Holdings 在 10 个国家有直接业务。Otsuka Holdings 拥有 25家子公司，其中包括 Astex、Astex Pharmaceuticals 和 Cambridge Isotope Laboratories。
他们在：
高管
查看带有其 245 名主要高管的组织结构图
Otsuka Holdings 搜索最多的简介
- Tatsuo Higuchi, President, Chief Executive Officer, Chairman of Th...
- Yukio Matsutani, Independent Director
- Ko Sekiguchi, Independent Director
创建提醒
跟踪 Otsuka Holdings 的高管变动
健康
Otsuka Holdings 拥有 1,982 家竞争者，其中包括 UnitedHealth Group (美国(美洲))、UnitedHealthcare (美国(美洲)) 和 Siemens Healthineers (德国)。
Popular M&A news in 健康
- Oura Health 刚刚宣布为 200 筹款数百万美元。 (公布2024十二月20号).
- Neuronetics 已收购 Greenbrook TMS (公布2024十二月10号).
- Cleerly 刚刚宣布为 106 筹款数百万美元。 (公布2024十二月9号).
健康 行业的其他推荐联系人
消息
Otsuka Holdings 的最新新闻稿
- Otsuka and Jolly Good initiate the sale of FACEDUO Dementia Care Support VR｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Pharmaceutical Launches POCARI SWEAT Basketball Dream Project to Promote Sports and International Exchanges｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Obtains Exclusive Global Licensing Rights from Ionis to Ulefnersen, a Potential Treatment for Amyotrophic Lateral Sclerosis Caused by Mutations in the Fused in Sarcoma Gene (FUS-ALS) ｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka launches Lupkynis® in Japan｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults｜News Releases | Otsuka Pharmaceutical Co., Ltd.
- Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company’s Carbon Neutrality Initiative | Otsuka Group News | Otsuka Holdings Co., Ltd.searchsearchBack ButtonSearch IconFilter Icon
- HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -｜News Releases | Otsuka Pharmaceutical C
- View more press releases Close
通过电子邮件
